UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 68

Sortiert nach

The class III variant of the epidermal growth factor receptor (EGFRvIII): characterization and utilization as an immunotherapeutic target

Journal of neurovirology, 1998, Vol.4 (2), p.148-158

1998

Link zum Volltext

Verfügbarkeit prüfen

Phase II Trial of Gefitinib in Recurrent Glioblastoma

Journal of clinical oncology, 2004-01, Vol.22 (1), p.133-142

2004

Link zum Volltext

Verfügbarkeit prüfen

EGF mutant receptor vIII as a molecular target in cancer therapy

Endocrine-related cancer, 2001-06, Vol.8 (2), p.83-96

2001

Link zum Volltext

Verfügbarkeit prüfen

Glycoprotein Nonmetastatic Melanoma Protein B, a Potential Molecular Therapeutic Target in Patients with Glioblastoma Multiforme

Clinical cancer research, 2006-04, Vol.12 (7), p.1970-1982

2006

Link zum Volltext

Verfügbarkeit prüfen

Epidermal Growth Factor Receptor VIII Peptide Vaccination Is Efficacious against Established Intracerebral Tumors

Clinical cancer research, 2003-09, Vol.9 (11), p.4247-4254

2003

Link zum Volltext

Verfügbarkeit prüfen

Combination therapy of inhibitors of epidermal growth factor receptor/vascular endothelial growth factor receptor 2 (AEE788) and the mammalian target of rapamycin (RAD001) offers improved glioblastoma tumor growth inhibition

Molecular cancer therapeutics, 2005-01, Vol.4 (1), p.101-112

2005

Link zum Volltext

Verfügbarkeit prüfen

Resistance to Tyrosine Kinase Inhibition by Mutant Epidermal Growth Factor Receptor Variant III Contributes to the Neoplastic Phenotype of Glioblastoma Multiforme

Clinical cancer research, 2004-05, Vol.10 (9), p.3216-3224

2004

Link zum Volltext

Verfügbarkeit prüfen

Cell surface localization and density of the tumor-associated variant of the epidermal growth factor receptor, EGFRvIII

Cancer research (Chicago, Ill.), 1997-09, Vol.57 (18), p.4130-4140

1997

Link zum Volltext

Verfügbarkeit prüfen

Poliovirus receptor CD155-targeted oncolysis of glioma

Neuro-oncology (Charlottesville, Va.), 2004-07, Vol.6 (3), p.208-217

2004

Link zum Volltext

Verfügbarkeit prüfen

Monoclonal antibodies against EGFRvIII are tumor specific and react with breast and lung carcinomas and malignant gliomas

Cancer research (Chicago, Ill.), 1995-07, Vol.55 (14), p.3140-3148

1995

Link zum Volltext

Verfügbarkeit prüfen

Development of a Syngeneic Rat Brain Tumor Model Expressing EGFRvIII and Its Use for Molecular Targeting Studies with Monoclonal Antibody L8A4

Clinical cancer research, 2005-01, Vol.11 (1), p.341-350

2005

Link zum Volltext

Verfügbarkeit prüfen

Phase I Trial Results of Iodine-131–Labeled Antitenascin Monoclonal Antibody 81C6 Treatment of Patients With Newly Diagnosed Malignant Gliomas

Journal of clinical oncology, 2000-11, Vol.18 (22), p.3862-3872

2000

Link zum Volltext

Verfügbarkeit prüfen

Iodine-131-labeled antitenascin monoclonal antibody 81C6 treatment of patients with recurrent malignant gliomas: phase I trial results

Journal of clinical oncology, 1998-06, Vol.16 (6), p.2202-2212

1998

Link zum Volltext

Verfügbarkeit prüfen

Identifying potential tumor markers and antigens by database mining and rapid expression screening

Genome research, 2000-09, Vol.10 (9), p.1393

2000

Link zum Volltext

Verfügbarkeit prüfen

Receptor dimerization is not a factor in the signalling activity of a transforming variant epidermal growth factor receptor (EGFRvIII)

Biochemical journal, 1997-06, Vol.324 ( Pt 3) (3), p.855-861

1997

Link zum Volltext

Verfügbarkeit prüfen

Increased binding affinity enhances targeting of glioma xenografts by EGFRvIII‐specific scFv

International journal of cancer, 2000-12, Vol.88 (6), p.962-969

2000

Link zum Volltext

Verfügbarkeit prüfen

Immune Responses of Breast Cancer Patients to Mutated Epidermal Growth Factor Receptor (EGF-RvIII, {Delta}EGF-R, and de2-7 EGF-R)

The Journal of immunology (1950), 2004-11, Vol.173 (10), p.6472-6480

2004

Link zum Volltext

Verfügbarkeit prüfen

Monoclonal antibodies for brain tumour treatment

Expert opinion on biological therapy, 2004-09, Vol.4 (9), p.1453-1471

2004

Link zum Volltext

Verfügbarkeit prüfen

Glioma-associated Antigen Expression in Oligodendroglial Neoplasms: Tenascin and Epidermal Growth Factor Receptor

The journal of histochemistry and cytochemistry, 2000-08, Vol.48 (8), p.1103-1110

2000

Link zum Volltext

Verfügbarkeit prüfen

Improved targeting of an anti-epidermal growth factor receptor variant III monoclonal antibody in tumor xenografts after labeling using N-succinimidyl 5-iodo-3-pyridinecarboxylate

Cancer research (Chicago, Ill.), 1997-04, Vol.57 (8), p.1510-1515

1997

Link zum Volltext

Verfügbarkeit prüfen

Tumor antigens in astrocytic gliomas

Glia, 1995-11, Vol.15 (3), p.244-256

1995

Link zum Volltext

Verfügbarkeit prüfen

Prognostic Applications of the Epidermal Growth Factor Receptor and Its Ligand, Transforming Growth Factor-α

JNCI : Journal of the National Cancer Institute, 1998-06, Vol.90 (11), p.799-813

1998

Link zum Volltext

Verfügbarkeit prüfen

Monoclonal antibody therapy of human gliomas: current status and future approaches

Cancer and metastasis reviews, 1999, Vol.18 (4), p.451-464

1999

Link zum Volltext

Verfügbarkeit prüfen

Immunotoxins that target an oncogenic mutant epidermal growth factor receptor expressed in human tumors

Clinical cancer research, 1995-08, Vol.1 (8), p.859-864

1995

Link zum Volltext

Verfügbarkeit prüfen

Tenascin and microvessel stromal changes in patients with non-Hodgkin's lymphoma are isolated to the sites of disease and vary in correlation to disease activity

Leukemia & lymphoma, 2005-10, Vol.46 (10), p.1455-1462

2005

Link zum Volltext

Verfügbarkeit prüfen

1 – 25 von 68

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(65)
Mit Volltextzugriff
(59)

Publikationsform

Artikel
(68)

Sprache

Englisch
(68)
Japanisch
(10)

Erscheinungsjahr

n.n

Thema

Science & Technology
(67)
Life Sciences & Biomedicine
(66)
Humans
(56)
Animals
(44)
Biological And Medical Sciences
(38)
Mice
(33)
Medical Sciences
(31)
Oncology
(30)
Female
(20)
Neurosciences & Neurology
(19)
Cell Line
(18)
Mice, Nude
(16)
Neurology
(16)
Immunotherapy
(15)
Neurosciences
(15)
Antibodies, Monoclonal
(14)
Glioma - Immunology
(14)
Tumors Of The Nervous System. Phacomatoses
(14)
Pathology
(13)
Transplantation, Heterologous
(12)

15 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

The class III variant of the epidermal growth factor receptor (EGFRvIII): characterization and utilization as an immunotherapeutic target

Phase II Trial of Gefitinib in Recurrent Glioblastoma

EGF mutant receptor vIII as a molecular target in cancer therapy

Glycoprotein Nonmetastatic Melanoma Protein B, a Potential Molecular Therapeutic Target in Patients with Glioblastoma Multiforme

Epidermal Growth Factor Receptor VIII Peptide Vaccination Is Efficacious against Established Intracerebral Tumors

Combination therapy of inhibitors of epidermal growth factor receptor/vascular endothelial growth factor receptor 2 (AEE788) and the mammalian target of rapamycin (RAD001) offers improved glioblastoma tumor growth inhibition

Resistance to Tyrosine Kinase Inhibition by Mutant Epidermal Growth Factor Receptor Variant III Contributes to the Neoplastic Phenotype of Glioblastoma Multiforme

Cell surface localization and density of the tumor-associated variant of the epidermal growth factor receptor, EGFRvIII

Poliovirus receptor CD155-targeted oncolysis of glioma

Monoclonal antibodies against EGFRvIII are tumor specific and react with breast and lung carcinomas and malignant gliomas

Development of a Syngeneic Rat Brain Tumor Model Expressing EGFRvIII and Its Use for Molecular Targeting Studies with Monoclonal Antibody L8A4

Phase I Trial Results of Iodine-131–Labeled Antitenascin Monoclonal Antibody 81C6 Treatment of Patients With Newly Diagnosed Malignant Gliomas

Iodine-131-labeled antitenascin monoclonal antibody 81C6 treatment of patients with recurrent malignant gliomas: phase I trial results

Identifying potential tumor markers and antigens by database mining and rapid expression screening

Receptor dimerization is not a factor in the signalling activity of a transforming variant epidermal growth factor receptor (EGFRvIII)

Increased binding affinity enhances targeting of glioma xenografts by EGFRvIII‐specific scFv

Immune Responses of Breast Cancer Patients to Mutated Epidermal Growth Factor Receptor (EGF-RvIII, {Delta}EGF-R, and de2-7 EGF-R)

Monoclonal antibodies for brain tumour treatment

Glioma-associated Antigen Expression in Oligodendroglial Neoplasms: Tenascin and Epidermal Growth Factor Receptor

Improved targeting of an anti-epidermal growth factor receptor variant III monoclonal antibody in tumor xenografts after labeling using N-succinimidyl 5-iodo-3-pyridinecarboxylate

Tumor antigens in astrocytic gliomas

Prognostic Applications of the Epidermal Growth Factor Receptor and Its Ligand, Transforming Growth Factor-α

Monoclonal antibody therapy of human gliomas: current status and future approaches

Immunotoxins that target an oncogenic mutant epidermal growth factor receptor expressed in human tumors

Tenascin and microvessel stromal changes in patients with non-Hodgkin's lymphoma are isolated to the sites of disease and vary in correlation to disease activity

Suchergebnisse filtern